Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus R

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Free Report) have earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the company, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued a report on […]

Related Keywords

William Meury , Briggs Morrison , News Ratings For Syndax Pharmaceuticals Daily , Hedge Funds Weigh In On Syndax Pharmaceuticals , Syndax Pharmaceuticals Inc , Metlife Investment Management , Syndax Pharmaceuticals Company Profile , Nasdaq , Syndax Pharmaceuticals , Blackrock Inc , Barclays , Analyst Recommendations For Syndax Pharmaceuticals , Syndax Pharmaceuticals Trading , Securities Exchange Commission , Insider Transactions At Syndax Pharmaceuticals , Jpmorgan Chase Co , Citigroup , York Mellon Corp , Get Free Report , Director Briggs Morrison , Director William Meury , Exchange Commission , New York Mellon Corp , Life Investment Management , Get Free , Syndax Pharmaceuticals Daily , Nasdaq Sndx , Sndx , Medical , Ratings , Consensus ,